PCV15 PREDICTORS OF THE COMBINED DIAGNOSIS HYPERLIPIDEMIA AND HYPERTENSION - A NHANES 2007-2008 STUDY  by Bhounsule, P. & Abughosh, S.
PCV10
THE EFFECT OF INTERACTIONS BETWEEN CLOPIDOGREL AND PROTON PUMP
INHIBITORS ON ADVERSE CARDIOVASCULAR OUTCOMES IN COMMERCIALLY
INSURED PATIENTS WITH ACUTE CORONARY SYNDROME
Bhurke S, Martin B, Li C, Franks A, Bursac Z, Said Q
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: Following a FDA warning in November 2009, significant controversy
exists regarding the outcomes of patients co-medicated with clopidogrel and
omeprazole after acute coronary syndrome (ACS). This study examined the effect
of proton pump inhibitors (PPI) –clopidogrel interactions on subsequent ACS emer-
gency department and inpatient visits.METHODS: This was a retrospective cohort
study of administrative claims data for a large nationally dispersed group of com-
mercially insured subjects between 2001 and 2008. Subjects age 18 years with a
diagnosis of ACS and at least one clopidogrel prescription within 90 days after the
diagnosis were included. The clopidogrel plus PPI (CPPI) group was defined as
subjects with a minimum of 7 days overlap between the PPI and clopidogrel pre-
scriptions. Subjects were followed from their first clopidogrel prescription until
they experienced a re-hospitalization or ER visit due to ACS, disenrolled or reached
the study end. CPPI group was matched 1:1 with clopidogrel group using propen-
sity scoring methods with calipers. Cox proportional hazards regression was used
to estimate the relative risk of an adverse cardiovascular event. RESULTS: Of the
10,101 patients taking clopidogrel, 16.98% (n1,716) were prescribed a PPI. Propen-
sity matching resulted in 1,697 patient pairs. The mean age was 61.50 years with a
mean follow up of 259 days and 69.64% were males. 13.20% (n224) had an ACS-
related re-hospitalization or ER visit in the clopidogrel group versus 16.32% (n277)
in the CPPI group. CPPI usewas not associatedwith a significantly increased risk
of adverse outcomes (HR1.221; 95% CI, 0.984-1.517) compared to clopidogrel users
not co-medicated with a PPI. CONCLUSIONS: Concurrent use of clopidogrel and
PPIs trended toward a non-significant increase in risk of adverse cardiovascular
outcomes for ACS patients, which suggests caution may be warranted when pre-
scribing a PPI with clopidogrel. Future studies should account for time dependence
of exposure.
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PNEUMONIA AFTER ACUTE ISCHEMIC STROKE: PREVALENCE, ASSOCIATED
FACTORS AND OUTCOMES
Al-Jabi SW1, Hassan Y1, Abd Aziz N1, Looi I2, Zyoud SH1
1Universiti Sains Malaysia (USM), Pinang, Malaysia, 2Pulau Pinang Hospital, Pinang, Malaysia
OBJECTIVES: Pneumonia is one of the most frequent medical complications of
acute ischemic stroke, often apparent early after stroke onset, and it is associated
with increased risk of death after stroke attack. We aimed to identify clinically
useful factors associatedwith pneumonia, and to examine the effect of pneumonia
on patient’s functional outcome at discharge and on in-hospital mortality after the
attack. METHODS: It is an evaluation of post-stroke pneumonia complication
among ischemic stroke patients attending a hospital inMalaysia fromNovember 1,
2008 to April 30, 2009. Data included demographic information, risk factors and
clinical characteristics. Functional outcome at discharge as measured by the Mod-
ified Barther Index (MBI) and in-hospital mortality were assessed. Poor outcome
was defined as MBI  75. SPSS version 15 was used for data analysis. RESULTS: A
total of 256 patients were studied, of which 33 (12.9%) experienced pneumonia
complication during hospitalization. The key baseline factors associated with the
occurrence of post-stroke pneumonia were total anterior circulation infarct (P 
0.001), moderate and severe Glasgow Coma Scale (P  0.001), atrial fibrillation (P 
0.035) and renal impairment (P  0.001). Moreover, 24 (60%) of dead cases were
suffering from pneumonia during hospitalization (P  0.001). Additionally, after
excluding the dead cases, 8 (9.2%) of patients discharged with poor functional
outcome were having pneumonia during their hospital stay (P  0.002).
CONCLUSIONS: Pneumonia is independently associatedwith ischemic stroke poor
outcome. Identification of medical history and clinical characteristics on admis-
sion can assist clinicians to identify patients at higher risk of developing post-
stroke pneumonia thus hastening the initiation of certain interventions to improve
patient outcome.
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IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS (DDIS) ON HEALTH
OUTCOMES AND COST TO MEDICAID: THE MONETARY BENFITS OF QUALITY
HEALTH CARE
Athavale AS, Banahan BFI, Mendonca CM
University of Mississippi, University, MS, USA
OBJECTIVES: To examine the impact of potential DDIs on health outcomes and the
associated cost to the Mississippi Medicaid program. METHODS: A retrospective
matched cohort study was conducted in Mississippi Medicaid enrollees for years
2002-2004. Enrollees were classified as exposed to a potential DDI if the object and
precipitant drugswere possessed concomitantly, with first day of overlap being the
DDI event date. Exposed enrollees were matched to enrollees taking object drugs
without a potential DDI based on demographic, comorbidity and object drug-re-
lated variables. Controls were assigned the event date for the matched exposed
case. Conditional logistic regression was used to analyze the effect on health out-
comes (hospitalizations and ER visits within 30 days of potential DDI) and paired
t-tests for costs to Mississippi Medicaid. RESULTS: DDIs with the greatest health
and economic effects included: ACE/ARBs –– odds ratio (OR) for hospitalizations 
1.75, OR for ER visits  1.39, difference in average per patient hospital payments
(	APPHP)  $124, and difference in average per patient ER payments (	APPERP) 
$63); beta blockers –– OR for hospitalizations  1.52, OR for ER visits  1.24 (n.s.),
	APPHP  $78.13, and 	APPERP  $43.67; clonidine –– OR for hospitalizations 
1.67, OR for ER visits  1.35, 	APPHP  $50, 	APPHP  $8.17; warfarin with quino-
lone ––OR for hospitalizations 1.17 (n.s.), OR for ER visits 1.27;	APPHP $83.35,
and 	APPERP $48.14); warfarin with thyroid hormones –– OR for hospitalizations
 2.47, OR for ER visits  1.96, 	APPHP  $106.03, and 	APPERP  $100.33.
CONCLUSIONS: Based on these findings, Medicaid intervention strategies to re-
duce the incidence of potential DDIs should be a cost-effectivemethod for improv-
ing health care quality and thus a priority for state Medicaid programs.
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BURDEN OF COMORBIDITIES AMONG PATIENTS WITH ATRIAL FIBRILLATION
LaMori JC1, Gross HJ2, Patel AA1, Crain M3, DiBonaventura MD2, Mody SH1, Schein J1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Kantar Health, New York, NY,
USA, 3Centocor Ortho Biotech Services, LLC, Virginia Beach, VA, USA
OBJECTIVES: Atrial fibrillation (AF) may manifest with comorbidities. We exam-
ined the prevalence of comorbidities and general medication use among AF pa-
tients in order to assess total disease burdenMETHODS: Data were obtained from
the 2009 National Health and Wellness Survey (N75,000), an annual cross-sec-
tional Internet-based survey of adults in the United States. In addition to demo-
graphics and medication use, patients with AF also reported on their comorbid
conditions. Using demographic and patient characteristics, a CHADS2 score (an
index of stroke risk) was calculated for each patient. RESULTS: A total of 1297
patients reported a diagnosis of AF. Themean agewas 64.9 years (SD 12.2), and 65%
were male. In addition to AF, these patients reported comorbidities in various
organ systems, including 90% with a cardiovascular condition, 62% with a urolog-
ical condition, 42% with a respiratory condition, and 41% with a gastrointestinal
condition. Specific comorbid conditions reported in this AF patient population in-
cluded hypertension in 72% of patients, history of myocardial infarction in 21% of
patients, heartburn/gastroesophageal reflux disease in 29% of patients, and aller-
gies/hay fever in 29% of patients. Themean Charlson Comorbidity Index score was
1.53 for all patients. Almost half of patients (46%) had a CHADS2 score of 2. The
percentage of patients reporting current medication use included: 71% for AF, 64%
for hypertension, 50% for hyperlipidemia, 29% for arrhythmia, 24% for diabetes,
and 26% for gastrointestinal medications. Overall, 43% of patients with AF were
using an anticoagulant medication. CONCLUSIONS: This self-reported national
survey identified AF patients as having a high comorbidity burden, with conditions
affecting a variety of organ systems. Medications used to treat a variety of condi-
tions are also highly prevalent and should be taken into account in managing
patients with AF.
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DYSPEPSIA AND DISEASE BURDEN AMONG PATIENTS WITH ATRIAL
FIBRILLATION (AF)
LaMori JC1, Gross HJ2, Patel AA1, Crain M3, DiBonaventura MD2, Mody SH1, Schein J1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Kantar Health, New York, NY,
USA, 3Centocor Ortho Biotech Services, LLC, Virginia Beach, VA, USA
OBJECTIVES: Many agents used in treating AF have potential gastrointestinal (GI)
tolerability issues. Treatment-related adverse GI events are a common reason for
noncompliance to treatment. The current analysis describes the prevalence of
dyspepsia in relation to anticoagulant use among AF patients. METHODS: Data
were obtained from the 2009 National Health and Wellness Survey (N75,000), an
annual cross-sectional Internet-based survey of US adults. Respondents answered
general demographic and health-related questions. A CHADS2 score (an index of
stroke risk) was calculated for each patient using demographic and clinical
characteristics. RESULTS: A total of 1297 patients (1.7%) reported a diagnosis of AF.
Of these patients, 535 (41%) also reported a physician-diagnosed GI condition; 449
of these (84%) were consistent with dyspepsia (ulcers, abdominal bloating, abdom-
inal pain, gastroesophageal reflux disease/acid reflux, or heartburn). Compared
with AF patients without dyspepsia (n848), those with dyspepsia were younger
(mean 62.9 vs. 66.0 years, p0.05) and more likely to be female (43% vs. 31%,
p0.05). AF patients with dyspepsia were in poorer health than those without
dyspepsia, as evidenced by a higher CHADS2 score (1.9 vs. 1.4, p0.05); this differ-
ence was more pronounced in patients aged 65 years and in those with CHADS2
score2. Despite this, significantly fewer AF patients with than without dyspepsia
were taking a prescription medication to treat AF (67% vs. 73%, p0.05) or an anti-
coagulant for stroke prevention (35% vs. 47%, p0.05). CONCLUSIONS:One-third of
AF patients in this analysis had dyspepsia. These patients reported a greater dis-
ease burden and stroke risk relative to AF patients without dyspepsia. Significantly
fewer AF patients with than those without dyspepsia were taking a prescription to
treat AF or an anticoagulant for stroke prevention. Poor GI tolerability may be
significant in the AF population and should be considered when adherence to
medication is critical, such as in high-risk populations.
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PREDICTORS OF THE COMBINED DIAGNOSIS HYPERLIPIDEMIA AND
HYPERTENSION - A NHANES 2007-2008 STUDY
Bhounsule P, Abughosh S
University of Houston, Houston, TX, USA
OBJECTIVES: Cardiovascular disease (CVD) remains the leading cause of death in
the United State (US). Both hyperlipidemia and hypertension are known risk fac-
tors for CVD. Tobacco use augments this risk by lowering the HDL cholesterol,
increasing blood clotting, and acutely elevating blood pressure. The objective of
this study was to examine predictors of having both co-morbidities including de-
mographic characteristics and smoking status METHODS: A retrospective cross-
sectional study was conducted using the NHANES 2007-2008 database, a stratified
multistage probability sample of the civilian non-institutionalized US population.
The outcome variable was defined as being diagnosed with both hypertension and
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hyperlipidemia based on the standardized interview conducted by the National
Center for Health Statistics (NCHS) among adults  18 years. Descriptive statistics
and multivariate logistic regression were used to determine predictors having the
combined diagnosis including the following independent variables: gender, age,
race, ethnicity, urban/rural status and smoking status. Statistical analysis was
performed using SAS 9.2. RESULTS: The total sample included 33,994 individuals
and the combined diagnosis of hypertension and hyperlipidemia was reported in
4.49% of the sample. Of these, 61.51% were females and 41% were aged between
60-75 years. Most (73.25%) of these patients were whites and more than half
(54.75%) reported to have smoked at least 100 cigarettes in their lifetime, while
34.01% were current smokers. In the multivariate model, significant predictors of
the combined diagnosis included female gender (OR 0.689; 95% CI 0.594 – 0.798;
p.0001), age 60-75 years vs. younger age (OR1.627; 95% CI1.296 – 2.042;
p.0001),MexicanAmerican race vs. non-hispanics (OR 0.611; 95%CI 0.49 – 0.76;
p.0007) and current smokers. (OR1.374; 95% CI1.08-1.75; p.0001).
CONCLUSIONS: Our findings emphasize the importance of developing effective
intervention strategies that help smokers quit and may reduce prevalence of hy-
perlipidemia with hypertension along with the accompanying cardiovascular risk.
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MANAGING GROWING POPULATION OF TYPE-2 DIABETES FROM COMMUNITY
TO TEACHING HOSPITALS IN CHINA
Zhang D1, Ji L2, Hu D2
1VitalStrategic Research Institute, Berwyn, PA, USA, 2Peking University People’s Hospital,
Beijing, China
OBJECTIVES: Diabetes prevalence has grown rapidly in China. As the largest epi-
demiology and clinical outcomes assessment program, China Cardiometabolic
Registries (CCMR), has been designed to establish systemic evaluation on disease
progression and influencing factors. The Nationwide Assessment of CVD Risk Fac-
tors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with type
2 Diabetes (T2D) (CCMR-3B) was one of the CCMR studies and was conducted to
assess the clinical outcomes of current treatment patterns.METHODS: This was a
cross sectional, observational study. Patients were recruited from community (tier
1), regional (tier 2), and teaching hospitals (tier 3) from all 6 major geographic
regions in China, by cardiologists, nephrologists and endocrinologist, and internal
medicine. RESULTS: A total of 5099 T2D patients was included for this analysis.
Across all hospitals, 55% and 34% of the patients had hypertension (HTN) or dis-
lipidemia (DYLP), respectively, while 33% had neither. No difference was found
between hospitals regarding the proportion of patients reaching target control
(HbA1C7.0%, BP130/80 mmHg, LDL2.6 mmol/L) in those who also have HTN or
DYLP (ranging from 4.4 % to 6.6% for the HTN group and 6.9% to8.0% for the DYLP
group). However a trend toward a better HbA1C control in patients without HTN or
DYLP (diabetes only) in larger hospitalswas seen (10.7%, 11.2%, 15.4% in tier 1, 2 and
3 hospitals, respectively). A trend toward more use of multiple oral anti-diabetic
drugs and insulin was also seen in larger hospitals. CONCLUSIONS: Better HbA1c
control seen in larger hospitals was associated with more aggressive use of antidi-
abetic treatment. The control of cardiovascular risk factors, blood glucose, blood
pressure, and blood lipid, in diabetes patients with HTN or DYLP remains to be
challenging in all hospital settings.
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PREDICTORS OF TIME TO DISCONTINUE BETA-BLOCKER FOLLOWING ACUTE
MYOCARDIAL INFARCTION: AN ANALYSIS OF THE MEDICARE 5% NATIONAL
SAMPLE DATA 2006-2007
Lokhandwala T, Yang Y, Thumula V, Bentley JP, Strum M, Banahan BF, Null K
University of Mississippi, University, MS, USA
OBJECTIVES: To study the predictors of beta-blocker therapy discontinuation
among post myocardial infarction (MI) patients enrolled in Medicare. METHODS:
This is a retrospective cohort study utilizing a Medicare 5% national sample claims
data for 2006-2007. Medicare beneficiaries with continuous Part A, B, and D enroll-
ment in 20062007, and who were hospitalized for an acute MI in the first six
months of 2006 were identified using a validated algorithm, requiring a hospital-
ization episode 3 and 180 days with an ICD-9-CM of 410.x1 as principal or sec-
ondary diagnosis. Post-MI patientswith a filled prescription for beta-blockerwithin
90 days of discharge were followed until the end of the study period. Time to
discontinuation was defined as days from initiation of therapy to a gap of90 days
in therapy. Survival curves were modeled using the Kaplan-Meier technique, and
potential predictors of therapy discontinuation, including demographic character-
istics, comorbid conditions and concomitant medications were estimated using
Cox proportional hazards regression. RESULTS: Of the 2,505 subjects who met our
inclusion criteria, 65.1% were females, 83.3% were Caucasian, mean age 78.6 (8.2)
years. About 15% of them discontinued therapywithin sixmonths and around 35%
discontinued within a year. Males weremore likely to discontinue therapy as com-
pared to females (HR1.166; [1.020-1.334]; p0.0245) and Caucasians (HR0.674;
[0.557-0.815]; p0.0001) were less likely to discontinue therapy compared to Afri-
can Americans. The results of Cox proportional hazardsmodel shows that diabetes
(HR1.224; [1.069-1.402]; p0.0035), dyslipidemia (HR0.675; [0.565-0.807];
p.0001), CHF (HR1.234; [1.03-1.478]; p0.0223), cerebrovascular disease
(HR1.206; [1.057-1.376]; p0.0054) and COPD (HR1.209; [1.061-1.377]; p0.0043)
were significant predictors of time to discontinuation. Patients on concomitant
statin treatment were less likely to discontinue beta-blocker therapy (HR0.774;
[0.667-0.899]; p0.0008). CONCLUSIONS: Many patients initiating beta-blocker
therapy post MI fail to consistently remain on the treatment. Several demographic
characteristics and comorbid conditions are associated with this behavior.
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MEDICATION ADHERENCE AND HOSPITALIZATION AMONG CHRONIC HEART
FAILURE MEDICARE BENEFICIARIES WITH AND WITHOUT DEPRESSION
Chhabra P, Dutcher SK, Rattinger GB, Zuckerman IH, Simoni-Wastila L, Gottleib SS,
Stuart B
University of Maryland, Baltimore, Baltimore, MD, USA
OBJECTIVES: Adherence to chronic heart failure (CHF) medications decreases pre-
ventable hospitalizations. Nevertheless, CHF rarely occurs without concomitant
conditions. We sought to: 1) evaluate impact of comorbid depression on CHFmed-
ication use and adherence among Medicare beneficiaries with CHF(CHF_MED-
_BEN); 2) examine relationships between CHF medication adherence and out-
comes; and 3) determine if depression modifies this relationship. METHODS: We
employed a cross-sectional design of 2006-2007 CMS Medicare Chronic Condition
Warehouse (CCW) database. Sample was restricted to CHF_MED_BEN with Medi-
care A,B and D to observe all prescription and medical claims. We classified indi-
viduals with CHF and depression if theymet the CCWdefinitions. Adherencemea-
sures included any use (binary) and medication possession ratio (MPR) for
evidence-based CHF medications (EBM). Multivariable analyses included an inter-
action term to test effect modification of depression on the relationship between
EBM adherence and number of hospitalizations. Relative rates of hospitalization
are reported with 95%CI. RESULTS: A total of 151,924 CHF_MED_BENmet inclusion
criteria. Mean agewas 75.9/-12.0 years; 68%were female. 25%had depression and
they were significantly younger(74.5 vs. 76.3 years,p0.001) and more likely to be
female(75% vs. 66%,p0.001) compared to non-depressed CHF_MED_BEN. A signif-
icantly lower proportion of depressed CHF_MED_BEN received EBM (75% vs.
79%,p0.001), compared to non-depressed CHF_MED_BEN.MedianMPRwas 0.92 in
both groups. A higher proportion of depressed CHF_MED_BEN was hospitalized
(76% vs. 63%,p0.001) and re-hospitalized (40.5% vs. 38.6%,p0.001) compared to
non-depressed CHF_MED_BEN. In multivariable models, depression modified the
effect of adherence on hospitalizations (interaction term p0.001): compared to
high adherence (MPR0.9), poor adherence (MPR0.5) was associated with a 24%
(95%CI 1.20-1.28) increased hospitalization rate among non-depressed CHF_MED-
_BEN and a 45% (95%CI 1.37-1.54) increased hospitalization rate among depressed
CHF_MED_BEN. CONCLUSIONS: Depression was not associated with poor EBM ad-
herence among CHF_MED_BEN. Poor EBM adherence was associated with in-
creased hospitalization in both depressed and non-depressed groups, with a
greater effect among depressed CHF_MED_BEN.
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A BAYESIAN MULTIPLE TREATMENT COMPARISON OF PULMONARY ARTERIAL
HYPERTENSION DRUG CLASSES BASED ON THE RISK OF MORTALITY
REPORTED IN CLINICAL TRIALS
Mutebi A, Malone D
University of Arizona, Tucson, AZ, USA
OBJECTIVES: To compare the performance of pulmonary arterial hypertension
(PAH) drug classes based on the risk of mortality reported in clinical trials, and
inform a revised PAH treatment algorithm. METHODS: The study used Bayesian
Analysis Using Gibbs Sampling in Windows (WinBUGS) and Monte Carlo Simula-
tions to conduct a multiple treatment comparison of placebo and three PAH drug
classes; prostanoids (Treprostinil & Iloprost), endothelin-receptor antagonists
(Bosentan, Sitaxsentan, & Ambrisentan), and phosphodiesterase (sildenafil). Direct
and indirect pairwise odds ratios (OR) were obtained. Published PAH studies
through 2010 were identified from MEDLINE (PubMed) database and an extended
manual search was also conducted based on references from identified studies.
Inclusion was restricted to randomized controlled trials lasting at least 12 weeks
and at most 16 weeks, with subjects having either idiopathic or associated PAH,
and studies that reported mortality as an endpoint. Studies that compared combi-
nations of drugs were excluded from the analysis. Results are reported in OR with
95% credible intervals. RESULTS: In total 8 studies (20 treatment arms, 2,015 sub-
jects enrolled) were included in the analysis. 2 studies were 3-arm trials and 1 was
a 4-arm trial.With placebo as the reference class, the OR ofmortalitywas 1.00 (0.06,
4.20) for prostanoids; 1.14 (0.15, 4.69) for endothelin-receptor antagonists and 0.62
(0.05, 2.83) for phosphodiesterase. Using prostanoids as the reference class, the OR
of mortality was 4.28 (0.10, 23.10) for endothelin-receptor antagonists and 2.40
(0.04, 12.66) for phosphodiesterase. Using endothelin-receptor antagonists as the
reference class, the OR of mortality was 1.11 (0.04, 5.55) for phosphodiesterase.
None of the ORs were statistically significant. CONCLUSIONS: Based on the risk of
mortality reported in clinical trials, there is no statistically significant difference
among PAH drug classes. Including more studies/drugs and the use of different
PAH outcomes could inform a more detailed comparison.
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PERSISTENCE WITH STATINS AND PRIMARY PREVENTION OF
CARDIOVASCULAR EVENTS: A POPULATION-BASED COHORT STUDY
Chodick G, Shalev V, Goldstein I, Porath A, Simah V
Maccabi Healthcare Services, Tel Aviv, Israel
OBJECTIVES: To evaluate the association between persistent use of statins and the
risk of acute cardiovascular events among primary prevention patients in commu-
nity settings. METHODS: A population-based retrospective cohort among 171,846
adults aged 45-75, with no history of any cardiovascular disease, who began statin
therapy between 1998 and 2009. Proportion of days covered (PDC) with statins was
measured by the number of dispensed prescriptions during follow-up period.
Study endpoint was occurrence of a major cardiovascular event, which comprised
myocardial infarction or performance of a cardiac revascularization procedure
RESULTS: The fully adjusted survival analysis indicated a significant negative as-
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